All In Biotech

Drug Trial Radar · NCT01242202

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients

Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With an α-Glucosidase Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With an α-Glucosidase Inhibitor Alone

Last checked: Nov 20, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Oct 21, 2010

Primary completion

May 25, 2012

Study completion May 25, 2012

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Nov 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and α-glucosidase inhibitor in Japanese patients with type 2 diabetes mellitus.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • ipragliflozinDrug

    oral

  • alpha glucosidase inhibitorDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in HbA1cTime frame: baseline and 52 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chūbu, Japan

  • Site not named

    Hokkaido, Japan

  • Site not named

    Kansai, Japan

  • Site not named

    Kantou, Japan

  • Site not named

    Kyushu, Japan

  • Site not named

    Tōhoku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.